Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

85.09EUR
25 Apr 2017
Change (% chg)

-- (--)
Prev Close
€85.09
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,428,603
52-wk High
€86.05
52-wk Low
€62.50

Select another date:

Tue, Apr 25 2017

BRIEF-Regeneron says FDA approved for praluent injection

* Regeneron and Sanofi announce FDA approval of a new once-monthly dosing option for Praluent (Alirocumab) injection

BRIEF-Sanofi Genzyme announces positive new six-year data from analysis of lemtrada

* Sanofi genzyme - announced positive new six-year investigational data from post-hoc analysis of extension study of lemtrada (alemtuzumab)

BRIEF-Sanofi and Regeneron announce FDA approval of a once-monthly dosing option for Praluent

* Sanofi and Regeneron announce FDA approval of a new once-monthly dosing option for Praluent (alirocumab) injection

Sanofi files U.S. antitrust lawsuit against Mylan over EpiPen

France's Sanofi SA on Monday sued Mylan NV, accusing the pharmaceutical company of engaging in illegal conduct to squelch competition to its EpiPen allergy treatment, which has been at the center of a public debate over drug prices.

UPDATE 1-Sanofi files U.S. antitrust lawsuit against Mylan over EpiPen

April 24 France's Sanofi SA on Monday sued Mylan NV, accusing the pharmaceutical company of engaging in illegal conduct to squelch competition to its EpiPen allergy treatment, which has been at the center of a public debate over drug prices.

Sanofi files U.S. antitrust lawsuit against Mylan over EpiPen

Sanofi SA on Monday sued Mylan NV, accusing the pharmaceutical company of engaging in illegal conduct to squelch competition to its EpiPen allergy treatment, which has been at the center of a public debate over drug prices.

Sanofi files U.S. antitrust lawsuit against Mylan over EpiPen

April 24 Sanofi SA on Monday sued Mylan NV, accusing the pharmaceutical company of engaging in illegal conduct to squelch competition to its EpiPen allergy treatment, which has been at the center of a public debate over drug prices.

EMA panel recommends nod for Sanofi, Regeneron's arthritis drug

A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis.

EMA panel recommends nod for Sanofi, Regeneron's arthritis drug

April 21 A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis.

BRIEF-EU Medicines Agency recommendations for April 2017

* EU Medicines Agency recommends approval granting of a marketing authorisation for Sandoz's Rixathon Non-Hodgkin's Lymphoma (NHL), chronic lymphocytic leukaemia

Select another date:

More From Around the Web